APA

Greenwald M., Szczepanski L., Kennedy A., Veenhuizen M., Komocsar W. J., Polasek E., Guerrettaz K., Berclaz P. & Lee C. (20150716). A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis. : Arthritis research & therapy.

Chicago

Greenwald Maria, Szczepanski Leszek, Kennedy Alastair, Veenhuizen Melissa, Komocsar Wendy J, Polasek Emery, Guerrettaz Kelly, Berclaz Pierre-Yves and Lee Chin. 20150716. A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis. : Arthritis research & therapy.

Harvard

Greenwald M., Szczepanski L., Kennedy A., Veenhuizen M., Komocsar W. J., Polasek E., Guerrettaz K., Berclaz P. and Lee C. (20150716). A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis. : Arthritis research & therapy.

MLA

Greenwald Maria, Szczepanski Leszek, Kennedy Alastair, Veenhuizen Melissa, Komocsar Wendy J, Polasek Emery, Guerrettaz Kelly, Berclaz Pierre-Yves and Lee Chin. A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis. : Arthritis research & therapy. 20150716.